Nov 18, 2022 11:51 AM (GMT+8) · EqualOcean
RongCan Biotech (Chinese:荣灿生物), a nucleic acid technology independent innovation platform, announced its completion of a pre-Series A financing round worth tens of millions of CNY. This funding round was led by a well-known medical health industry fund, with HaoYue Capital (Chinese:浩悦资本) acting as the exclusive financial advisor. The funds will accelerate product R&D and team construction and advance the company’s leading pipelines into clinical study. Founded in 2020, RongCan Biotech focuses on developing and industrializing nucleic acid-based therapeutics, striving to become a whole-industry-chain company covering from mRNA sequential design and synthesis, and LNP-based delivery systems to finished mRNA-based pharmaceutical products.